TABLE 1.
Liver transplant recipients with COVID‐19 demographic, comorbidities and underlying liver disease. Data summary for individual patient (pt), including age in years (y), sex (male: M or female: F), race, body mass index (BMI), date of liver transplant (LT), indication for primary LT and for redo or for relisting
| Pt | Age (y) | Sex | Race | BMI | Date LT (s) | Indication LT/relisting/redoLT | Comorbidity | In‐patient stay (d) | Admission reason |
|---|---|---|---|---|---|---|---|---|---|
| 1 a | 36 | M | Cypriot | 18 | 2011 | Familial amyloid polyneuropathy/cholangiopathy | Nil | 25 | Blocked PTC |
| 2 a | 54 | M | British | 30.9 | 2004 | Chronic Budd Chiari/small vessel VOD, ascites | T2DM, hypertension, high cholesterol | 21 | Cough, pyrexia |
| 3 | 54 | M | British | 27.9 |
2009 2014 |
Primary sclerosing cholangitis/primary sclerosing cholangitis | UC + ileostomy | 4 | Headache, vomiting, photophobia, pyrexia |
| 4 | 23 | M | British | 24.4 |
2017 24/1/19 20/10/19 |
Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis/ductopenic rejection/antibody‐mediated rejection | Nil | 7 | Chest wall pain and fever |
| 5 | 28 | M | British Indian | 21.4 | 1998 20/2/20 | PFIC3/ALF | Nil | 75 | ALF second to variceal bleed |
Abbreviations: ALF, acute liver failure; PFIC3, primary familial intra‐hepatic cholestasis type 3; PTC, percutaneous transhepatic cholangiogram; T2DM, type 2 diabetes mellitus; UC, ulcerative colitis; VOD, veno‐occlusive disease.
a
Marks patients who are relisted.